# A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A

> **NCT03020160** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 48 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** Emicizumab

## Key facts

- **NCT ID:** NCT03020160
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-30
- **Primary completion:** 2017-12-15
- **Final completion:** 2022-06-29
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2023-01-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03020160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03020160, "A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03020160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*